Continuous glucose monitors (CGMs) have moved from a luxury for select type 1 diabetes patients to a standard tool for nearly anyone using insulin — and increasingly for type 2 patients without insulin too. Medicare expanded coverage dramatically in 2023, and most commercial plans followed. But the details of who qualifies, what you pay, and whether the device runs through your pharmacy benefit or durable medical equipment benefit varies widely. This guide walks through the 2026 coverage landscape so you can get a CGM at the lowest cost your plan allows.
What a CGM Does
- Tiny sensor inserted under the skin (typically on the upper arm or abdomen) reads glucose every 1 to 5 minutes
- Sensor lasts 10 to 14 days (Dexcom G7, Libre 3) or 365 days (Eversense, implanted)
- Data displayed on a phone app or dedicated receiver
- Alerts for high or low glucose
- Trend arrows for direction of change
- Sharing with caregivers, family, or doctor
- Integration with insulin pumps for automated dosing
2026 Coverage by Insurance Type
| Insurance | T1D Coverage | T2D on Insulin | T2D Not on Insulin |
|---|---|---|---|
| Medicare | Yes | Yes (any insulin use) | Yes if documented hypoglycemia |
| Medicaid | Yes (all states) | Yes in most states | Varies by state |
| Commercial PPO/HMO | Yes | Most plans | Plan-dependent |
| ACA Marketplace | Yes | Most plans | Plan-dependent |
| VA | Yes | Yes | Yes if clinically indicated |
| TRICARE | Yes | Yes | Limited |
| Self-pay | Full retail | Full retail | Stelo or Lingo OTC ($89/mo) |
Medicare CGM Coverage Rules (2023 Expansion)
Medicare’s April 2023 update meaningfully broadened CGM access. To qualify under Medicare Part B durable medical equipment:
- You have diabetes (any type)
- You either use insulin (any frequency — even one shot of basal counts) OR have a history of problematic hypoglycemia documented by your clinician
- You have a prescription from a clinician treating your diabetes
- You have a recent in-person clinical visit (within 6 months) documenting the prescription
- You have follow-up visits every 6 months to renew coverage
- You agree to use the CGM as prescribed
The 20 percent Part B coinsurance applies — typically $40 to $80 per month out of pocket unless covered by Medigap. CGM transmitters, sensors, and (if applicable) receivers are included.
Commercial Insurance Coverage
Commercial plan coverage varies, but common patterns:
- Type 1 diabetes — almost universal coverage; prior auth often automatic with diagnosis
- Type 2 on multiple daily insulin injections (MDI) — usually covered; prior auth typical
- Type 2 on basal insulin only — covered by many plans following Medicare’s expansion model
- Type 2 on oral meds with hypoglycemia history — increasingly covered; requires documentation
- Type 2 stable on metformin — usually not covered; consider OTC Stelo or Lingo
- Gestational diabetes — coverage varies; some plans approve during pregnancy
Pharmacy vs DME Benefit
| Feature | Pharmacy Benefit | Durable Medical Equipment |
|---|---|---|
| Where you get it | Retail pharmacy (CVS, Walgreens, Walmart, mail-order) | DME supplier (Edgepark, Byram, CCS Medical) |
| Most Dexcom orders | Yes (pharmacy) | Sometimes |
| Most Libre orders | Yes (pharmacy) | Some via DME |
| Eversense | No | Yes — clinician inserts |
| Pump-integrated CGM | Pharmacy for CGM, DME for pump | Sometimes bundled |
| Typical 30-day cost (commercial) | $30 to $80 copay | 20% coinsurance after deductible |
| Speed to start | 1 to 3 days | 1 to 4 weeks paperwork |
| Prior auth burden | Lower | Higher |
Out-of-Pocket Costs Without Insurance
| CGM | Manufacturer | Cash Price / Month | Notes |
|---|---|---|---|
| Dexcom G7 | Dexcom | $300 to $400 | 10-day sensors; 3 per month; receiver optional |
| Libre 3 | Abbott | $140 to $200 | 14-day sensors; 2 per month |
| Libre 3 Plus | Abbott | $160 to $220 | 15-day sensors; longer wear |
| Eversense E3 | Senseonics | ~$125 per month average | Implant lasts 365 days; ~$1,500/yr + insertion |
| Stelo | Dexcom (OTC) | ~$89 | OTC; 2 sensors lasting 15 days each; T2D not on insulin or non-diabetics |
| Lingo | Abbott (OTC) | ~$89 | OTC; 14-day sensors; metabolic wellness positioning |
Documentation Needed for Prior Authorization
- Active diabetes diagnosis (ICD-10 code)
- Insulin prescription with dosing schedule (if applicable)
- Recent A1C result
- Recent hypoglycemia documentation (clinician notes, severe events, ER visits)
- History of self-monitoring blood glucose (frequency)
- Statement of medical necessity from clinician
- Treatment goal that CGM is expected to support (reducing hypos, improving time-in-range)
- Confirmation of in-person clinic visit within recent months
Common Reasons for Denial and How to Appeal
- “Not on insulin” — supply documented hypoglycemia, request reconsideration under Medicare-aligned criteria
- “Not enough fingersticks logged” — submit recent SMBG logs or pharmacy fill history for test strips
- “Diagnosis not type 1” — supply C-peptide result or autoantibody testing if available; otherwise emphasize hypoglycemia or pump use
- “Other CGM tried first” — request formulary alternative or document specific reason (skin reaction, accuracy)
- “Letter of medical necessity not provided” — your clinician supplies; can usually be filed within 24-72 hours
- External appeal — independent reviewer if internal appeals fail; state-regulated plans have this right
See our prior authorization guide for the full appeals process.
Medicaid CGM Coverage by State
Medicaid CGM coverage has expanded significantly since 2020. As of 2026, the majority of state Medicaid programs cover CGMs for insulin-using patients; coverage for non-insulin users varies. States with the most generous coverage include California, Washington, Oregon, Minnesota, Colorado, and New York. States with more restrictive policies require documentation of multiple daily injections or severe hypoglycemia. Contact your state Medicaid agency for current rules.
OTC CGMs: Stelo and Lingo
The 2024 launch of the first over-the-counter CGMs changed access for type 2 patients not on insulin:
- Stelo by Dexcom — $89 per 2-sensor pack (about a month); FDA-cleared for adults with type 2 diabetes not on insulin and for non-diabetics tracking metabolic health
- Lingo by Abbott — $89 per 2-sensor pack; positioned as wellness/metabolism tracker
- No prescription, no insurance involvement, available at Walmart, Amazon, and manufacturer websites
- HSA/FSA eligible for diabetic users with a Letter of Medical Necessity
- Not for type 1 diabetes (no alarms, no integration with pumps)
CGM Sample Cost Calculator
| Scenario | Annual Cost |
|---|---|
| Medicare + Medigap, Dexcom G7 | $0 to $200 |
| Medicare without Medigap, Dexcom G7 | $800 to $1,200 |
| Commercial PPO, Dexcom G7, $40 pharmacy copay | $480 |
| Commercial HDHP before deductible, Dexcom G7 | $3,600 to $4,800 |
| Medicaid (covered state) | $0 to $50 |
| Self-pay Dexcom G7 | $3,600 to $4,800 |
| Self-pay Libre 3 | $1,700 to $2,400 |
| Self-pay Stelo or Lingo | $1,068 |
Switching Between CGMs
You can switch between Dexcom and Libre as your needs and insurance change. Common reasons:
- Pump compatibility (Tandem t:slim X2 and Medtronic 780G work with specific CGMs)
- Skin sensitivity to one brand’s adhesive
- Pharmacy cost differences after a plan change
- Sensor longevity preferences (Libre 14-day vs Dexcom 10-day)
- Alert customization needs
Your prescriber writes a new Rx; the old CGM remains usable until its sensor expires.
What CGMs Do Not Replace
- Fingerstick verification during rapid glucose changes
- Calibration in some older systems
- Hospital glucose protocols (most hospitals still use fingersticks)
- Driving/aviation regulatory contexts (varies)
- Insulin dosing decisions when sensor shows error or “???” reading
See our overview of how often to check blood glucose for context on combining CGM with fingersticks.
Common Pitfalls
- Letting Rx run out at the pharmacy — sensors stop arriving mid-cycle
- Forgetting the 6-month renewal visit for Medicare
- Not appealing a denial — about 60 percent of CGM denials are overturned on first appeal
- Mixing pharmacy and DME orders and ending up with double charges
- Not using HSA/FSA for OTC CGMs as a diabetes patient (requires LMN)
- Skipping prior authorization renewal — typically yearly for commercial plans
Related Reading
See insulin pump insurance coverage for related DME devices, Medicare diabetes coverage for broader rules, prior authorization for diabetes drugs, diabetes tracking apps for software that pairs with CGMs, and our treatment hub.
The Bottom Line
CGM coverage is broader in 2026 than it has ever been. Medicare covers any insulin user or anyone with documented hypoglycemia. Commercial insurance generally covers type 1 patients and insulin-using type 2 patients, with growing coverage for non-insulin type 2. Most CGMs run through pharmacy benefits like a prescription — Dexcom G7 and Libre 3 are usually a copay at your retail pharmacy. Out-of-pocket without insurance, Dexcom runs $300 to $400 monthly, Libre about $150, and over-the-counter Stelo or Lingo about $89. Prior authorization is the norm; documentation including diabetes diagnosis, insulin use or hypoglycemia history, and a medical necessity letter is required. If denied, appeal — most denials are overturned with proper documentation. Talk to your endocrinologist or primary care doctor about which CGM fits your situation, and ask your pharmacist to clarify pharmacy versus DME billing before you order.
